- Japanese trading house Mitsubishi Corp. decided Thursday to withdraw from the Vinh Tan 3 coal-fired power plant project in Vietnam amid growing international concern about climate change, Nikkei has learned.
- Visit Vietnam Insider hompage for more stories.
The project is separate from the Vung Ang 2 coal power plant, which the governments of Japan and Vietnam are pursuing together. Environmental activist Greta Thunberg has called for the cancellation of Vung Ang 2.
Vinh Tan 3, planned for Binh Thuan Province in southern Vietnam, is scheduled to come online in 2024. The 2-gigawatt plant is expected to feature cutting-edge ultra-supercritical technology.
OneEnergy, a joint venture of Mitsubishi and Hong Kong’s CLP group, holds a 49% interest in the $2 billion project. State-owned Electricity of Vietnam owns another 29%. Chinese companies are handling materials procurement, construction and equipment delivery.
The banking consortium behind Vinh Tan 3 includes Industrial and Commercial Bank of China. Standard Chartered and HSBC have pulled financing from the power plant.
Unlike Vung Ang 2, Vinh Tan 3 is not a national project, and the start date for construction has already been delayed, making it easier to bow out.
This marks Mitsubishi’s first time withdrawing from a coal plant project. The trading house has said it will not build any new facilities of this type after Vung Ang 2. It plans to contribute to development on power projects that are less harmful to the environment, including liquefied natural gas and renewables such as solar.
@Nikkei Asia
Share this:
Related
Other News
- Baijiayun to Acquire Beijing Hydrogen, an AI-enabled Marketing Service Provider in China
- JCET Accelerates Technology Upgrades and Transformation in 2022, Maintaining a Leading Edge in High Value-added Applications
- NAVER Joins Hands with Two Saudi Arabian Ministries for Digital Transformation
- Vestas extends O&M service contract with availability guarantee for Eurus Energy's wind farm in Operation for more than 20 years
- ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization